Gelonghui May 27| Affected by performance growthzodiaccasinonodepositbonus, Shijiazhuang Pharmaceutical Group (1093zodiaccasinonodepositbonus.HK) rose sharply at the opening of the afternoon, and the current increase has expanded to more than 7%, at 6zodiaccasinonodepositbonus.83 Hong Kong dollars, with a total market value of HK$81 billion. The company announced at noon that its turnover in the first quarter was 8.983 billion yuan (the same below), a year-on-year increase of 11.5%zodiaccasinonodepositbonus; Net profit was 1.613 billion yuan, a year-on-year increase of 12.9%.

Excluding fair value losses on financial assets at fair value through profit or loss and share-based employee compensation expenses, underlying profit attributable to shareholders was 1.724 billion yuan, a year-on-year increase of 11.6%.

Year-to-date, the Group has 1 innovative drug approved for marketing in China for new indications, obtained 16 clinical trial approvals, and 2 generic drugs have obtained drug registration approvals; 2 innovative drugs under development in North America have obtained clinical trial approval.